European Journal of Cancer
Volume 46, Issue 1 , Pages 72-83 , January 2010

Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)

Presented in part at the 44th Annual Meeting of the American Society of Clinical Oncology, May 30–June 3, 2008, Chicago, Illinois.

  • Stefan Sleijfer

      Affiliations

    • Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
    • Corresponding Author InformationCorresponding author: Address: Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands. Tel.: +31 (0)10 7041733; fax: +31 (0)10 7041003.
    • ,
  • Monia Ouali

      Affiliations

    • EORTC Data Center, Brussels, Belgium
    • ,
  • Martine van Glabbeke

      Affiliations

    • EORTC Data Center, Brussels, Belgium
    • ,
  • Anders Krarup-Hansen

      Affiliations

    • Department of Oncology, University Hospital Herlev, Copenhagen, Denmark
    • ,
  • Sjoerd Rodenhuis

      Affiliations

    • Department of Medical Oncology, National Cancer Institute, Amsterdam, The Netherlands
    • ,
  • Axel Le Cesne

      Affiliations

    • Department of Medical Oncology, Institute Gustave Roussy, Villejuif, France
    • ,
  • Pancras C.W. Hogendoorn

      Affiliations

    • Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    • ,
  • Jaap Verweij

      Affiliations

    • Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
    • ,
  • Jean-Yves Blay

      Affiliations

    • Department of Medical Oncology, Centre Leon Berard, Lyon, France

Received 29 July 2009 ,Revised 13 September 2009 ,Accepted 17 September 2009.

References 

  1. Hogendoorn PC, Collin F, Daugaard S, et al. Changing concepts in the pathological basis of soft tissue and bone sarcoma treatment. Eur J Cancer. 2004;40:1644–1654
  2. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: a randomised trial. Lancet. 2004;364:1127–1134
  3. Verweij J, van Oosterom A, Blay J-Y, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer. 2003;39:2006–2011
  4. McArthur GA, Demetri GD, Van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005;23:866–873
  5. Sleijfer S, Seynaeve C, Verweij J. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist. 2005;10:833–841
  6. Tascilar M, Loos WJ, Seynaeve C, et al. The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. Oncologist. 2007;12:1351–1360
  7. Lorigan P, Verweij J, Papai Z, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol. 2007;25:3144–3150
  8. Verma S, Younus J, Stys-Norman D, et al. Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. Cancer Treat Rev. 2008;34:339–347
  9. Van Glabbeke M, Van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens – a European Organization of Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1999;17:150–167
  10. Mouridsen HT, Bastholt L, Somers R, et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol. 1987;23:1477–1483
  11. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcoma: a randomized study of the European Organization of Research and Treatment of Cancer Soft Tissue and Bone sarcoma Group. J Clin Oncol. 1995;13:1537–1545
  12. Nielsen OS, Dombernowsky P, Mouridsen H, et al. Epirubicin is not superior to doxorubicin in the treatment of advanced soft tissue sarcoma. The experience of the EORTC Soft Tissue and Bone sarcoma Group. Sarcoma. 2000;4:31–35
  13. Verweij J, Lee SM, Ruka W, et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European Organization of Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 2000;18:2081–2086
  14. Van Oosterom AT, Mouridsen HT, Nielsen OS, et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer. 2002;38:2397–2406
  15. Nielsen OS, Judson I, Van Hoesel Q, et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2000;36:61–67
  16. Schütte J, Mouridsen HT, Steward W, et al. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. Eur J Cancer Clin Oncol. 1990;26:558–561
  17. Le Cesne A, Judson I, Crowther D, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization of Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 2000;18:2676–2684
  18. Steward WP, Verweij J, Somers R, et al. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic soft tissue sarcomas: a study of the European Organization of Research and Treatment of Cancer Soft Tissue and Bone sarcoma Group. J Clin Oncol. 1993;11:15–21
  19. Klimm B, Engert A. Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignancies. Nature Clin Pract Oncol. 2008;5:316–323
  20. Karavasilis V, Seddon BM, Ashley S, et al. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma. Retrospective analysis and identification of prognostic factors in 488 patients. Cancer. 2008;112:1585–1591
  21. Antman K, Crowley J, Balcerak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993;11:1276–1285
  22. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993;11:1269–1275
  23. Spurrell EL, Fisher C, Thomas JM, Judson IR. Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital. Ann Oncol. 2005;16:437–444
  24. Jones RL, Fisher C, Al-Muderis O, Judson IR. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2003;41:2853–2860

PII: S0959-8049(09)00719-9

doi: 10.1016/j.ejca.2009.09.022

European Journal of Cancer
Volume 46, Issue 1 , Pages 72-83 , January 2010

Article Tools

* Image Usage & Resolution